Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany

European Journal of Health Economics

Volumn 14, Issue 6, 2013, Pages 1015-1026

  Ultsch, Bernhard ^a,b   Köster, Ingrid ^c   Reinhold, Thomas ^b   Siedler, Anette ^a   Krause, Gérard ^a,d   Icks, Andrea ^e   Schubert, Ingrid ^c   Wichmann, Ole ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Cost of illness; Epidemiology; Germany; Herpes zoster; Postherpetic neuralgia

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; AMITRIPTYLINE; BENZOCAINE; CAPSAICIN; CARBAMAZEPINE; DESIPRAMINE; DICLOFENAC; DIPYRONE; FAMCICLOVIR; GABAPENTIN; IBUPROFEN; IDOXURIDINE; IMIPRAMINE; LIDOCAINE; NORTRIPTYLINE; PHENYTOIN; PREGABALIN; TILIDINE; TRAMADOL; VALACICLOVIR;

ARTICLE; COST BENEFIT ANALYSIS; COST OF ILLNESS; DECISION MAKING; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HERPES ZOSTER; HUMAN; INCIDENCE; MEDICAL LEAVE; POSTHERPETIC NEURALGIA; PRESCRIPTION; PRIORITY JOURNAL;

ABSENTEEISM; GERMANY; HEALTH EXPENDITURES; HEALTH SERVICES; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MODELS, ECONOMIC; NEURALGIA, POSTHERPETIC;

EID: 84888437840     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-012-0452-1     Document Type: Article

References (64)

1. Wutzler, P.; Färber, I.; Wagenpfeil, S.; Bisanz, H.; Tischer, A.: Seroprevalence of varicella-zoster virus in the German population. Vaccine 20(1-2), 121-124 (2001)
2. Breuer, J.; Whitley, R.: Varicella zoster virus: natural history and current therapies of varicella and herpes zoster. Herpes 14(Suppl 2), 25-29 (2007)
3. Hope-Simpson, R.E.: The nature of herpes zoster: a long-term study and a new hypothesis. Proc. R. Soc. Med. 58, 9-20 (1965)
4. Wittek, M.; Doerr, H.W.; Allwinn, R.: Varicella and herpes zoster. Part 1: virology, epidemiology, clinical picture, laboratory diagnostics. Med Klin (Munich) 105(5), 334-338 (2010). doi: 10.1007/s00063-010-1061-3
5. Schmader, K.; Gnann Jr, J.W.; Watson, C.P.: The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J. Infect. Dis. 197(Suppl 2), S207-S215 (2008). doi: 10.1086/522152
6. Drolet, M.; Brisson, M.; Levin, M.J.; Schmader, K.E.; Oxman, M.N.; Johnson, R.W.; et al.: A prospective study of the herpes zoster severity of illness. Clin. J. Pain 26(8), 656-666 (2010). doi: 10.1097/AJP.0b013e3181eef686
7. Opstelten, W.; Eekhof, J.; Neven, A.K.; Verheij, T.: Treatment of herpes zoster. Can. Fam. Physician 54(3), 373-377 (2008)
8. Forbes, H.; Thomas, S.; Langan, S.: The epidemiology and prevention of herpes zoster. Curr. Dermatol. Rep. 1(1), 39-47 (2012). doi: 10.1007/s13671-011-0004-4
9. Edmunds, W.J.; Brisson, M.; Rose, J.D.: The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 19(23-24), 3076-3090 (2001). doi: 10.1016/S0264-410X(01)00044-5
10. Hope-Simpson, R.E.: Postherpetic neuralgia. J. R. Coll. Gen. Pract. 25(157), 571-575 (1975)
11. Jericho, B.G.: Postherpetic neuralgia: a review. Internet J. Pain Symptom Control Palliat. Care 8(1) (2010). doi: 10.5580/124b
12. EMA: European Public Assessment Report (EPAR) for ZOSTAVAX summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR---Product-Information/human/000674/WC500053462.pdf (2006). Accessed 18 March 2011
13. Oxman, M.N.; Levin, M.J.; Johnson, G.R.; Schmader, K.E.; Straus, S.E.; Gelb, L.D.; et al.: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352(22), 2271-2284 (2005). doi: 10.1056/NEJMoa051016
14. Tseng, H.F.; Smith, N.; Harpaz, R.; Bialek, S.R.; Sy, L.S.; Jacobsen, S.J.: Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 305(2), 160-166 (2011). doi: 10.1001/jama.2010.1983
15. Schmader, K.E.; Levin, M.J.; Gnann, J.W.; McNeil, S.A.; Vesikari, T.; Betts, R.F.; et al.: Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin. Infect. Dis. (2012). doi: 10.1093/cid/cir970
16. GlaxoSmithKline: Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 50 Years [ClinicalTrials.gov Identifier NCT01165177]. http://clinicaltrials.gov/ct2/show/NCT01165177?term= herpes+zoster&spons=GlaxosmithKline&age=12&phase=2&rank=1 (2011). Accessed 10 December 2011
17. MoH: Gesetzliche Krankenversicherung Mitglieder, mitversicherte Angehörige und Krankenstand Monatswerte Januar bis February 2012. http://bundesgesundheitsministerium.de/fileadmin/dateien/Downloads/Statistiken/ GKV/Mitglieder-Versicherte/KM1-Januar-Februar-2012.pdf (2012). 15 October 2012
18. Ihle, P.; Köster, I.; Herholz, H.; Rambow-Bertram, P.; Schardt, T.; Schubert, I.: Versichertenstichprobe AOK Hessen/KV Hessen - Konzeption und Umsetzung einer personenbezogenen Datenbasis aus der Gesetzlichen Krankenversicherung. Das Gesundheitswesen 67, 638-645 (2005). doi: 10.1055/s-2005-858598
19. Swart, E.; Ihle, P.; Geyer, S.; Grobe, T.; Hofmann, W.: GPS - good practice secondary data analysis. Working group for the survey and utilization of secondary data (AGENS) of the German Society for Social Medicine and Prevention (DGSMP). Gesundheitswesen 67(06), 416-421 (2005)
20. Annemans, L.; Bresse, X.; Gobbo, C.; Papageorgiou, M.: Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J. Med. Econ. 13(3), 537-551 (2010)
21. WHO: List of ICD-10 classifications. http://apps.who.int/classifications/ apps/icd/icd10online/ (2007). Accessed 30 November 2011
22. Ultsch, B.; Siedler, A.; Rieck, T.; Reinhold, T.; Krause, G.; Wichmann, O.: Herpes zoster in Germany: quantifying the burden of disease. BMC Infect. Dis. 11(1), 173 (2011)
23. Gross, G.; Schofer, H.; Wassilew, S.; Friese, K.; Timm, A.; Guthoff, R.et al.: Herpes zoster guideline of the German Dermatology Society (DDG). J. Clin. Virol. 26(3), 277-289; discussion 291-273 (2003). doi: 10.1016/S1386-6532(03) 00005-2
24. Brisson, M.: Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality. Can. J. Public Health 99(5), 383-386 (2008)
25. Gauthier, A.; Breuer, J.; Carrington, D.; Martin, M.; Remy, V.: Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol. Infect. 137(1), 38-47 (2009). doi: 10.1017/ S0950268808000678
26. Gonzalez Chiappe, S.; Sarazin, M.; Turbelin, C.; Lasserre, A.; Pelat, C.; Bonmarin, I.; et al.: Herpes zoster: burden of disease in France. Vaccine 28(50), 7933-7938 (2010)
27. Max, M.; Schafer, S.; Culnane, M.; Smoller, B.; Dubner, R.; Gracely, R.: Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 38(9), 1427 (1988)
28. Opstelten, W.; Mauritz, J.W.; de Wit, N.J.; van Wijck, A.J.; Stalman, W.A.; van Essen, G.A.: Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam. Pract. 19(5), 471-475 (2002)
29. van Hoek, A.J.; Gay, N.; Melegaro, A.; Opstelten, W.; Edmunds, W.J.: Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 27(9), 1454-1467 (2009). doi: 10.1016/j.vaccine.2008. 12.024
30. Dworkin, R.H.; Portenoy, R.K.: Pain and its persistence in herpes zoster. Pain 67(2-3), 241-251 (1996)
31. Yawn, B.P.: Post-shingles neuralgia by any definition is painful, but is it PHN? Mayo Clin. Proc. 86(12), 1141-1142 (2011). doi: 10.4065/mcp.2011.0724
32. Schreyogg, J.; Tiemann, O.; Busse, R.: Cost accounting to determine prices: how well do prices reflect costs in the German DRG-system? Health Care Manag. Sci. 9(3), 269-279 (2006)
33. IQWiG: Cost estimation - working paper, Version 1.0. https://www.iqwig. de/download/Working-Paper-Cost-Estimation.pdf (2009). Accessed 22 November 2011
34. DESTATIS: Lohnnebenkosten im Verhältnis zu den Bruttolöhnen und -gehältern im Jahr 2010. http://www.destatis.de/jetspeed/portal/cms/Sites/ destatis/Internet/DE/Presse/pm/2011/04/PD11--143--624,templateId=renderPrint. psml (2011). Accessed 6 February 2012
35. Krauth, C.; Hessel, F.; Hansmeier, T.; Wasem, J.; Seitz, R.; Schweikert, B.: Empirical standard costs for health economic evaluation in Germany - a proposal by the working group methods in health economic evaluation. Gesundheitswesen 67(10), 736-746 (2005). doi: 10.1055/s-2005-858698
36. DESTATIS: Verdienste und Arbeitskosten - Verdienststrukturerhebung 2006, Verdienste nach Berufen (2009). https://www.destatis.de/DE/Publikationen/ Thematisch/VerdiensteArbeitskosten/VerdiensteBerufe/ VerdienstenachBerufe5621108069004.pdf?--blob=publicationFile. Accessed 6 Mar 2012
37. DiCiccio, T.J.; Efron, B.: Bootstrap confidence intervals. Stat. Sci. 11(3), 189-228 (1996)
38. DESTATIS: Bevölkerung und Erwerbstätigkeit - Bevölkerungsfortschreibung (2010). https://www.destatis.de/DE/ Publikationen/Thematisch/Bevoelkerung/Bevoelkerungsstand/ Bevoelkerungsfortschreibung2010130107004.pdf?--blob=publicationFile. Accessed 6 Mar 2012
39. DESTATIS: Consumer price overall index (2011). http://www.destatis.de/ jetspeed/portal/cms/Sites/destatis/Internet/EN/Content/Statistics/TimeSeries/ EconomicIndicators/BasicData/Content100/vpi102a.psml. Accessed 8 Dec 2011
40. Welte, R.; Feenstra, T.; Jager, H.; Leidl, R.: A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 22(13), 857-876 (2004). doi: 10.2165/00019053-200422130-00004
41. OECD: Country statistical profiles. http://www.oecd.org/country/ (2011). Accessed 18 Jan 2012
42. Paul, E.; Thiel, T.: Epidemiology of varicella zoster infection. Results of a prospective study in the Ansbach area. Hautarzt 47(8), 604-609 (1996)
43. Schiffner-Rohe, J.; Jow, S.; Lilie, H.M.; Köster, I.; Schubert, I.: Herpes zoster in Deutschland - Eine retrospektive analyse von GKV-Daten. MMW Fortschr. Med. Orig. IV/2009(151), 193-197 (2009)
44. Gialloreti, L.; Merito, M.; Pezzotti, P.; Naldi, L.; Gatti, A.; Beillat, M.; et al.:: Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect. Dis. 10(1), 230 (2010)
45. Donahue, J.G.; Choo, P.W.; Manson, J.E.; Platt, R.: The incidence of herpes zoster. Arch. Intern. Med. 155(15), 1605-1609 (1995)
46. Cebrian-Cuenca, A.; Diez-Domingo, J.; San-Martin-Rodriguez, M.; Puig-Barbera, J.; Navarro-Perez, J.: Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian Community of Spain. BMC Infect. Dis. 11(1), 302 (2011)
47. Pierik, J.; Gumbs, P.; Fortanier, S.; Van Steenwijk, P.; Postma, M.: Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands. BMC Infect. Dis. 12(1), 110 (2012)
48. Insinga, R.P.; Itzler, R.F.; Pellissier, J.M.; Saddier, P.; Nikas, A.A.: The incidence of herpes zoster in a United States administrative database. J. Gen. Intern. Med. 20(8), 748-753 (2005). doi: 10.1111/j.1525-1497.2005.0150.x
49. Leung, J.; Harpaz, R.; Molinari, N.-A.; Jumaan, A.; Zhou, F.: Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin. Infect. Dis. 52(3), 332-340 (2011). doi: 10.1093/cid/ciq077
50. Tanuseputro, P.; Zagorski, B.; Chan, K.J.; Kwong, J.C.: Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine 29(47), 8580-8584 (2011). doi: 10.1016/j.vaccine. 2011.09.024
51. Yawn, B.P.; Saddier, P.; Wollan, P.C.; St Sauver, J.L.; Kurland, M.J.; Sy, L.S.: A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin. Proc. 82(11), 1341-1349 (2007)
52. Schmader, K.E.: Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin. J. Pain 18(6), 350-354 (2002)
53. Stein, A.N.; Britt, H.; Harrison, C.; Conway, E.L.; Cunningham, A.; Macintyre, C.R.: Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine 27(4), 520-529 (2009). doi: 10.1016/j.vaccine.2008.11.012
54. Schiffner-Rohe, J.; Köster, I.; Beillat, M.; Lilie, H.M.; Schubert, I.: Ressourcenverbrauch und Kosten von Herpes zoster und postherpetischer Neuralgie in Deutschland. Gesundh. Ökon. Qual. Manag.(EFirst) (2010). doi: 10.1055/s-0029-1245896
55. MacIntyre, C.R.; Chu, C.P.; Burgess, M.A.: Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia. Epidemiol. Infect. 131(1), 675-682 (2003)
56. Scott, F.T.; Johnson, R.W.; Leedham-Green, M.; Davies, E.; Edmunds, W.J.; Breuer, J.: The burden of Herpes Zoster: a prospective population based study. Vaccine 24(9), 1308-1314 (2006). doi: 10.1016/j.vaccine.2005.09.026
57. Insinga, R.P.; Itzler, R.F.; Pellissier, J.M.: Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans. Pharmacoeconomics 25(2), 155-169. doi: 10.1111/j.1525-1497.2005.0150.x (2007)
58. Hoffmann, F.; Icks, A.: Unterschiede in der Versichertenstruktur von Krankenkassen und deren Auswirkungen für die Versorgungsforschung: Ergebnisse des Bertelsmann-Gesundheitsmonitors. Gesundheitswesen (EFirst) (2011). doi: 10.1055/s-0031-1275711
59. Hoffmann, F.; Icks, A.: Diabetes prevalence based on health insurance claims: large differences between companies. Diabet. Med. 28(8), 919-923 (2011). doi: 10.1111/j.1464-5491.2011.03305.x
60. Damm, K.; Lange, A.; Zeidler, J.; Braun, S.; Graf von der Schulenburg, J.M.: Einführung des neuen Tätigkeitsschlüssels und seine Anwendung in GKV-Routinedatenauswertungen. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 55(2), 238-244 (2012). doi: 10.1007/s00103-011-1418-7
61. Zoike, E.; Bödeker, W.: Berufliche Tätigkeit und Arbeitsunfähigkeit. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 51(10), 1155-1163 (2008). doi: 10.1007/s00103-008-0650-2
62. Krauth, C.: Methoden der Kostenbestimmung in der gesundheitsö konomischen Evaluation. Gesundh. Ökon. Qual. Manag. 15(05), 251-259 (2010). doi: 10.1055/s-0029-1245680
63. Greiner, W.: 4. Die Berechnung von Kosten und Nutzen. In: Schöffski, O.; Graf von der Schulenburg, J.M. (eds.) Gesundheitsökonomische Evaluation, vol. 3. Springer, Heidelberg (2008)
64. Luce, B.R.; Manning, W.G.; Siegel, J.E.; Lipscomb, J.: Estimating costs in cost-effectiveness analysis. In: Gold, M.R.; Siegel, J.E.; Russell, L.B.; Weinstein, M.C. (eds.) Cost-Effectiveness in health and medicine. Oxford University Press, New York (1996)